Compare HROW & ODC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HROW | ODC |
|---|---|---|
| Founded | 1998 | 1941 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Miscellaneous manufacturing industries |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2008 | 1994 |
| Metric | HROW | ODC |
|---|---|---|
| Price | $28.30 | $73.79 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $62.63 | N/A |
| AVG Volume (30 Days) | ★ 635.5K | 97.2K |
| Earning Date | 11-09-2026 | 12-07-2026 |
| Dividend Yield | N/A | ★ 1.23% |
| EPS Growth | ★ 71.43 | 50.45 |
| EPS | N/A | ★ 1.69 |
| Revenue | N/A | ★ $493,844,000.00 |
| Revenue This Year | $28.13 | N/A |
| Revenue Next Year | $56.02 | N/A |
| P/E Ratio | ★ N/A | $43.48 |
| Revenue Growth | N/A | ★ 1.70 |
| 52 Week Low | $25.76 | $45.61 |
| 52 Week High | $54.98 | $107.00 |
| Indicator | HROW | ODC |
|---|---|---|
| Relative Strength Index (RSI) | 47.12 | 44.71 |
| Support Level | $27.75 | $69.95 |
| Resistance Level | $30.28 | $77.92 |
| Average True Range (ATR) | 1.66 | 2.68 |
| MACD | 0.31 | 0.74 |
| Stochastic Oscillator | 35.42 | 63.71 |
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
Oil-Dri Corp of America develops, manufactures, and markets sorbent products made predominantly from clay. Its absorbent offerings, which draw liquid up, include cat litter, floor products, toxin control substances for livestock, and agricultural chemical carriers. The company has two segments based on the different characteristics of two primary customer groups, namely the Retail and Wholesale Products Group, which derives maximum revenue, and the Business-to-Business Products Group. The company's products are sold under various brands such as Cat's Pride, Jonny Cat, Amlan, Agsorb, Verge, Pure-Flo, and Ultra-Clear.